levofloxacin has been researched along with vildagliptin in 1 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (vildagliptin) | Trials (vildagliptin) | Recent Studies (post-2010) (vildagliptin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 793 | 186 | 566 |
| Protein | Taxonomy | levofloxacin (IC50) | vildagliptin (IC50) |
|---|---|---|---|
| Dipeptidyl peptidase 9 | Bos taurus (cattle) | 0.68 | |
| Dipeptidyl peptidase IV | Porphyromonas gingivalis | 1.3 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.1496 | |
| Dipeptidyl peptidase 4 | Mus musculus (house mouse) | 0.051 | |
| Prolyl endopeptidase FAP | Homo sapiens (human) | 2.497 | |
| Dipeptidyl peptidase 8 | Homo sapiens (human) | 3.0627 | |
| Dipeptidyl peptidase 9 | Homo sapiens (human) | 0.4224 | |
| Dipeptidyl peptidase 2 | Homo sapiens (human) | 0.051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 other study(ies) available for levofloxacin and vildagliptin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |